Sunday, November 9 |
|
| 8:00 am - 8:10 am | President’s Welcome
and Meeting Overview Robert O. Dillman, MD Hoag Cancer Center President, SBT |
| 8:10 am - 8:15am | Welcome J. Carl Barrett, PhD Center for Cancer Research National Cancer Institute |
| 8:15 am - 9:05 am | Keynote Address: Hallmarks of Progress in Human Cancer Immunotherapy Steven A. Rosenberg, MD, PhD Center for Cancer Research National Cancer Institute |
| 9:05 am - 12:25 pm | Joint Session – Cytokines Co-Chairs: Jon M. Wigginton, MD Center for Cancer Research National Cancer Institute Paul Sondel, MD, PhD University of Wisconsin, Comprehensive Cancer Center |
| 9:05 am - 9:30 am | Interleukin18: A Potent Immunomodulatory
Dendrikine with Antitumor Activity Michael Lotze, MD University of Pittsburgh Medical Center |
| 9:30 am - 9:55 am | IL-15: Relevance in Biology and Disease
Michael Caligiuri, MD Ohio State University School of Medicine |
| 9:55 am - 10:20 am | The Laboratory and Clinical Biology
of Cancer Treatment with Tumor Reactive mAb Linked to
IL2 Paul Sondel, MD, PhD University of Wisconsin |
| 10:20 am - 10:40 am | Break |
| 10:40 am - 11:05 am | Preclinical and Clinical Investigation
of IL-12/Pulse IL-2 Jon M. Wigginton, MD National Cancer Institute - Center for Cancer Research |
| 11:05 am - 11:30 am | Phase I Trial of Twice-Weekly IV rhIL-
12 Plus Low-Dose SC IL-2 in Patients with Melanoma and
Renal Cell Cancer Jared Gollob, MD Beth Israel Deaconess Medical Center |
| 11:30 am - 11:55 am | IL-7: Emerging Role In Immunorestoration
and Vaccination Terry Fry, MD Center for Cancer Research National Cancer Institute |
| 11:55 am - 12:10 pm | Tumor Vaccination with Interleukin-12
and Granulocyte Macrophage-Colony Stimulating Factor-Encapsulated
Microspheres: Co-induction of Innate and Adaptive Immunity
Promotes Cure of Disseminated Disease Nejat K. Egilmez, PhD State University of New York at Buffalo |
| 12:10 pm - 12:25 pm | A Randomized Phase III Trial
of High- Dose Interleukin-2 David F. McDermott, MD Beth Israel Deaconess Medical Center |
| 12:25 pm - 2:15 pm | Box Lunch/Poster Session (authors must be present) |
| Concurrent Session 1 | Concurrent Session 2 | |
| 2:15 pm - 5:00 pm | Angiogenesis Co-Chairs: Steven K. Libutti, MD National Cancer Institute Michael O’ Reilly, MD |
Vaccine/Dendritic Cells Co-Chairs: Mary L. (Nora) Disis, MD University of Washington Walter Storkus, PhD |
| 2:15 pm - 2:40 pm | Phenotypic Diversity of Endothelial Cells
is Defined by the Organ Microenvironment Cheryl Baker, PhD University of Texas, M.D. Anderson Cancer Center |
Preclinical Strategies to Improve Dendritic
Cell-Based Tumor Vaccines James Mulé, PhD University of Michigan Medical Center |
| 2:40 pm - 3:05 pm | The Imaging of Angiogenesis Peter Choyke, MD Clinical Center, National Institutes of Health |
Dendritic Cells as Vectors and Targets
for Therapy Karolina Palucka, MD, PhD Baylor Institute for Immunology Research |
| 3:05 pm - 3:30 pm | Molecular Determinants of the Angiogenic
Switch and Tumor Progression Marsha Moses, PhD Harvard Medical School, Childrens Hospital |
Th1 and Th2 CD4+ T Cell Responses in
Melanoma and Renal Cell Carcinoma Walter Storkus, PhD University of Pittsburgh School of Medicine |
| 3:30 pm - 3:50 pm |
Break
|
|
| 3:50 pm - 4:15 pm | Angiogenesis and Gene Expression Profiling
Steven K. Libutti, MD Center for Cancer Research National Cancer Institute |
Multi-Epitope Peptide Vaccines with GMCSF
and IL2: CTL Responses in the Periphoral Blood and in
the Sentinel Immunized Node Craig L. Slingluff, Jr., MD University of Virginia Health Science Center |
| 4:15 pm - 4:30 pm | In Vivo Tumor Imaging Using Near Infrared
Labeled Endostatin Kevin Camphausen, MD Center for Cancer Research National Cancer Institute |
Immunization of HLA-A2+ Melanoma Patients
in the Adjuvant Setting with a Mutated gp100 Peptide (209-2M)
Induces Specific T Cell Immune Responses John W. Smith, II, MD Providence Cancer Center, Earle A. Chiles Research Institute |
| 4:30 pm - 4:45 pm | Peptide-Targeting IL-12 to avb3 Integrin
Mediates Potent Antiangiogenic Activity Erin Dickerson, PhD University of Wisconsin, School of Veterinary Medicine |
Transduction of Human Dendritic Cells
with a Melanoma Polyepitope Simultaneously Primes Multiple
T-cell Responses but Ultimately Results in Immunodominance Andrew Jackson, PhD St. James Hospital, Imperial Cancer Research Fund |
| 4:45 pm - 5:00 pm | Signal and Transcriptional Activation
of Proinflammatory and Proangiogenic Factor Expression
by Cancer Cells as a Target for Biological Therapy Carter Van Waes, MD, PhD Tumor Biology Section, HNSB, NIDCD |
Comparative Analysis of Necrotic and
Apoptotic Tumor Cells as a Source of Antigen(s) in Dendritic
Cell-Based Immunization Yoshihito Kotera, MD University of Michigan Medical Center |
| 5:00 pm - 6:30 pm |
Cocktail Reception
Hyatt Regency Bethesda |
|
